1MacPhee, CH, Moores, KE, Boyd, HF, et al. (1999) Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 338, 479–487.
2Sudhir, K (2006) Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction. Vasc Health Risk Manag 2, 153–156.
3Gazi, I, Lourida, ES, Filippatos, T, et al. (2005) Lipoprotein-associated phospholipase A2 activity is a marker of small dense LDL particles in human plasma. Clin Chem 51, 2264–2273.
4Serruys, PW, García-García, HM, Buszman, P, et al. (2008) Integrated biomarker and imaging study-2 investigators. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118, 1172–1182.
5Jenny, NS, Solomon, C, Cushman, M, et al. (2010) Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Atherosclerosis 209, 528–532.
6Kris-Etherton, PM, Harris, WS, Appel, LJ, et al. (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106, 2747–2757.
7Dyerberg, J, Bang, HO, Stoffersen, E, et al. (1978) Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet 2, 117–119.
8Pedersen, MW, Koenig, W, Christensen, JH, et al. (2009) The effect of marine omega-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr 48, 1–5.
9Nelson, TL, Hokanson, JE & Hickey, MS (2011) Omega-3 fatty acids and lipoprotein associated phospholipase A(2) in healthy older adult males and females. Eur J Nutr 50, 185–193.
11Davidson, MH, Maki, KC, Bays, H, et al. (2009) Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol 3, 332–340.
12Maki, KC, Bays, HE, Dicklin, MR, et al. (2011) Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol 5, 483–492.
13Saadatian-Elahi, M, Slimani, N, Chajès, V, et al. (2009) Plasma phospholipid fatty acid profiles and their association with food intakes: results from a cross-sectional study within the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 89, 331–346.
14Patel, PS, Sharp, SJ, Jansen, E, et al. (2010) Fatty acids measured in plasma and erythrocyte-membrane phospholipids and derived by food-frequency questionnaire and the risk of new-onset type 2 diabetes: a pilot study in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohort. Am J Clin Nutr 92, 1214–1222.
15Bild, DE, Bluemke, DA, Burke, GL, et al. (2002) Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 156, 871–881.
16Cao, J, Schwichtenberg, KA, Hanson, NQ, et al. (2006) Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin Chem 52, 2265–2272.
17Cushman, M, Cornell, ES, Howard, PR, et al. (1995) Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 41, 264–270.
18Brilakis, ES, Khera, A, McGuire, DK, et al. (2008) Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis 199, 110–115.
19Hatoum, IJ, Nelson, JJ, Cook, NR, et al. (2010) Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am J Clin Nutr 91, 786–793.
20Hirschler, V, Meroño, T, Maccallini, G, et al. (2011) Association of lipoprotein-associated phospholipase A(2) activity with components of the metabolic syndrome in apparently healthy boys. Cardiovasc Hematol Agents Med Chem 9, 78–83.
22Schmidt, EB, Koenig, W, Khuseyinova, N, et al. (2008) Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine omega-3 fatty acids. Atherosclerosis 196, 420–424.
23Spite, M & Serhan, CN (2010) Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 107, 1170–1184.
24Wu, X, Zimmerman, GA, Prescott, SM, et al. (2004) The p38 MAPK pathway mediates transcriptional activation of the plasma platelet-activating factor acetylhydrolase gene in macrophages stimulated with lipopolysaccharide. J Biol Chem 279, 36158–36165.
25Wang, WY, Li, J, Yang, D, et al. (2010) OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways. Cardiovasc Res 85, 845–852.
26Arita, M, Ohira, T, Sun, YP, et al. (2007) Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 178, 3912–3917.
27Chen, H, Li, D, Chen, J, et al. (2003) EPA and DHA attenuate ox-LDL-induced expression of adhesion molecules in human coronary artery endothelial cells via protein kinase B pathway. J Mol Cell Cardiol 35, 769–775.
28Madonna, R, Salerni, S, Schiavone, D, et al. (2011) Omega-3 fatty acids attenuate constitutive and insulin-induced CD36 expression through a suppression of PPAR α/γ activity in microvascular endothelial cells. Thromb Haemost 106, 500–510.
29Hennig, B, Lei, W, Arzuaga, X, et al. (2006) Linoleic acid induces proinflammatory events in vascular endothelial cells via activation of PI3K/Akt and ERK1/2 signaling. J Nutr Biochem 17, 766–772.
30Steffen, BT, Steffen, LM, Tracy, R, et al. (2012) Obesity modifies the association between plasma phospholipid polyunsaturated fatty acids and markers of inflammation: the Multi-Ethnic Study of Atherosclerosis. Int J Obes (Lond) 36, 797–804.
31Serhan, CN (2002) Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat 68–69, 433–455.
32Wu, SH, Liao, PY, Dong, L, et al. (2008) Signal pathway involved in inhibition by lipoxin A(4) of production of interleukins induced in endothelial cells by lipopolysaccharide. Inflamm Res 57, 430–437.
33Schaefer, EJ, McNamara, JR, Asztalos, BF, et al. (2005) Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 95, 1025–1032.
34Mohler, ER 3rd, Ballantyne, CM, Davidson, MH, et al. (2008) The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 51, 1632–1641.